+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Beigene"

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 82 Pages
  • Global
From
Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 155 Pages
  • Global
From
Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 504 Pages
  • Global
From
Gallbladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Gallbladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 195 Pages
  • Global
From
Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 4115 Pages
  • Global
From
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 1834 Pages
  • Global
From
Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 925 Pages
  • Global
From
Esophageal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Esophageal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 844 Pages
  • Global
From
Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 342 Pages
  • Global
From
Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 152 Pages
  • Global
From
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 100 Pages
  • Global
From
Thyroid Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Thyroid Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 1074 Pages
  • Global
From
Merkel Cell Carcinoma - Pipeline Review, H1 2020 - Product Thumbnail Image

Merkel Cell Carcinoma - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 535 Pages
  • Global
From
Oncology Markets for Tyrokinse Kinase Inhibitors - Product Thumbnail Image

Oncology Markets for Tyrokinse Kinase Inhibitors

  • Report
  • October 2021
  • 137 Pages
  • Global
From
Immune Checkpoint Inhibitors Market By Type, By Application: Global Opportunity Analysis and Industry Forecast, 2023-2032 - Product Thumbnail Image

Immune Checkpoint Inhibitors Market By Type, By Application: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • Report
  • December 2023
  • 248 Pages
  • Global
From
Global Immune Checkpoint Inhibitors Market Report and Forecast 2024-2032 - Product Thumbnail Image

Global Immune Checkpoint Inhibitors Market Report and Forecast 2024-2032

  • Report
  • May 2024
  • 140 Pages
  • Global
From
Loading Indicator

BeiGene is a market within the context of Oncology Drugs, which are drugs used to treat cancer. These drugs are used to target and destroy cancer cells, while minimizing damage to healthy cells. BeiGene is a biopharmaceutical company that develops and commercializes innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company focuses on developing therapies that target cancer cells with precision and accuracy, while also providing a safe and effective treatment for patients. BeiGene's portfolio includes a range of drugs, including small molecules, antibodies, and other biologics. The company also has a pipeline of novel therapies in development. BeiGene is one of many companies in the Oncology Drugs market. Other companies include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more